Department of Radiology, Stony Brook University, Stony Brook, New York 11794, United States.
Chemical and Physical Biology Graduate Program, Vanderbilt University, Nashville, Tennessee 37232, United States.
Mol Pharm. 2022 Jul 4;19(7):2268-2278. doi: 10.1021/acs.molpharmaceut.2c00102. Epub 2022 Jun 14.
Pretargeting is a technique that uses macromolecules as targeting agents for nuclear imaging and therapy with the goal of reducing the radiation toxicity to healthy tissues often associated with directly radiolabeled macromolecules. In pretargeting, a macromolecule is radiolabeled at the target site using a radiolabeled small molecule (radioligand) that interacts with the macromolecule with high specificity. We report an investigation of host-guest chemistry-driven pretargeting using copper-64 radiolabeled ferrocene (Fc; guest) compounds and a cucurbit[7]uril (CB7; host) molecule functionalized carcinoembryonic antigen targeting hT84.66-M5A monoclonal antibody (CB7-M5A). Two novel ferrocene-based radioligands ([Cu]Cu-NOTA-PEG-Fc and [Cu]Cu-NOTA-PEG-Fc) were prepared, and their stability, pharmacokinetic profile in healthy mice, and pretargeting performance in a subcutaneous BxPC3 human pancreatic cancer cell xenograft mouse model were compared. The antibody dosing was optimized using a zirconium-89 radiolabeled M5A antibody ([Zr]Zr-DFO-M5A) in a BxPC3 xenograft model, and the dosimetry of [Zr]Zr-DFO-M5A and the pretargeting approach were compared. Finally, the effects of varying lag times up to 9 days between CB7-M5A and radioligand injection were investigated. pretargeting studies with both ferrocene radioligands resulted in specific tumor uptake ( = 0.0006 and = 0.003) and also showed that the host-guest-based pretargeting approach excels with extended lag times up to 9 days with good tumor localization, suggesting that host-guest pretargeting may be suitable for use without clearing agents which have complicated clinical application of this technique. To our knowledge, the reported lag time of 9 days is the longest investigated lag time in any reported pretargeting studies.
前靶向是一种利用大分子作为核成像和治疗的靶向剂的技术,目的是降低与直接放射性标记大分子相关的健康组织的辐射毒性。在前靶向中,使用与大分子具有高特异性相互作用的放射性标记小分子(放射性配体)在靶位标记大分子。我们报告了使用铜-64 放射性标记的二茂铁(Fc;客体)化合物和葫芦[7]脲(CB7;主体)分子功能化癌胚抗原靶向 hT84.66-M5A 单克隆抗体(CB7-M5A)进行主体-客体化学驱动的前靶向研究。制备了两种新型基于二茂铁的放射性配体([Cu]Cu-NOTA-PEG-Fc 和 [Cu]Cu-NOTA-PEG-Fc),并比较了它们在健康小鼠中的稳定性、药代动力学特征以及在皮下 BxPC3 人胰腺癌细胞异种移植小鼠模型中的前靶向性能。使用锆-89 放射性标记的 M5A 抗体 ([Zr]Zr-DFO-M5A) 在 BxPC3 异种移植模型中优化了抗体剂量,并比较了 [Zr]Zr-DFO-M5A 的剂量学和前靶向方法。最后,研究了 CB7-M5A 和放射性配体之间的滞后时间长达 9 天变化对前靶向的影响。两种二茂铁放射性配体的前靶向研究均导致肿瘤摄取特异性(=0.0006 和=0.003),并且还表明基于主体-客体的前靶向方法具有长达 9 天的延长滞后时间的优势,具有良好的肿瘤定位,这表明主体-客体前靶向可能适合在不使用清除剂的情况下使用,清除剂的临床应用复杂。据我们所知,报告的 9 天滞后时间是任何报道的前靶向研究中最长的滞后时间。